Colorectal Cancer (eBook)

Diagnosis and Clinical Management

John H. Scholefield, Cathy Eng (Herausgeber)

eBook Download: PDF | EPUB

2014
John Wiley & Sons (Verlag)
978-1-118-33789-9 (ISBN)

Infos

Colorectal Cancer: Diagnosis and Clinical Management provides colorectal surgeons, gastroenterologists and oncologists with an authoritative, practical guide to best practice in the diagnosis and clinical management of colorectal cancer.

Covering all forms of treatment including surgery, chemotherapy and radiotherapy, it examines the various new and emerging therapies, new strategies for screening and prevention, as well as the latest guidance on the most challenging and controversial aspects of managing colorectal cancer.

The authors present important information on:

• Controversies in adjuvant chemotherapy
• Long versus short course radiotherapy
• Minimally invasive surgery and robotics
• Radical colonic resection

Each chapter contains key points, tips and tricks and clinical case studies to aid rapid browsing and knowledge of the basic principles, while self-assessment questions allow readers to test their clinical knowledge.

With leading international surgeons, gastroenterologists and oncologists combining to offer their considerable wealth of expertise and knowledge, Colorectal Cancer is a well-balanced, indispensable resource for all those involved in colorectal cancer management. 

 

John H. Scholefield, FRCS, ChM, Head, Division of GI Surgery & Professor of Surgery, University Hospital, Nottingham, UK

Cathy Eng, MD, FACP, Associate Professor & Associate Medical Director, Colorectal Center, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

Inhalt

Contributors, vii

Part 1 Diagnosis

1 Epidemiology, 3

Mala Pande & Marsha L. Frazier

2 Screening for colorectal cancer, 27

Robert JC Steele & Paula MacDonald

3 Management of adenomas, 51

Sunil Dolwani, Rajvinder Singh, Noriya Uedo & Krish
Ragunath

Part 2 Histopathology

4 How histopathology affects the management of the
multidisciplinary team, 69

Dipen Maru

Part 3 Surgical

5 Radical colonic resection, 87

Kenichi Sugihara, Yusuke Kinugasa & Shunsuke
Tsukamoto

6 ExtraLevator AbdominoPerineal Excision (ELAPE) for advanced
low rectal cancer, 104

Brendan J. Moran & Timothy J. Moore

7 Neoadjuvant therapy without surgery for early stage rectal
cancer?, 126

Thomas D. Pinkney & Simon P. Bach

8 Minimally invasive surgery for rectal cancer and robotics,
150

David Jayne & Gregory Taylor

9 Surgery for anal cancer, 163

John H. Scholefield

Part 4 Oncology

10 Controversies in adjuvant chemotherapy, 179

Stephen Staal, Karen Daily & Carmen Allegra

11 Long- versus short-course radiotherapy for rectal cancer,
200

Manisha Palta, Christopher G. Willett & Brian G.
Czito

12 More treatment is not necessarily better - limited
options for chemotherapeutic radiosensitization, 218

Daedong Kim

13 Controversies in advanced disease - surgical approaches
for metastatic resection, 227

Amanda B. Cooper, Thomas A. Aloia, Jean-Nicolas Vauthey &
Steven A. Curley

14 Controversies in chemotherapy in advanced colorectal cancer,
243

Ludmila Katherine Martin & Tanios Bekaii-Saab

Part 5 Outcomes

15 What is the role of surveillance for colorectal cancer?,
263

Daedong Kim

Part 6 Vignettes

16 The young patient with colorectal cancer - genetic
counseling discussion, 275

Sarah Bannon, Maureen E. Mork & Miguel A.
Rodriguez-Bigas

17 Best practices of supportive care while receiving
chemotherapy, 286

Maura Polansky

18 Palliative care vignettes, 292

Jenny Wei & Egidio Del Fabbro

Index, 299

Textauszug

CHAPTER 1
Epidemiology

Mala Pande & Marsha L. Frazier

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

KEY POINTS

Descriptive epidemiology: assessment of the distribution of colorectal cancer

• Ecological studies of populations are used to determine variation in rates. Incidence, mortality rate, time trends, and prevalence are some key measures.
• The burden of colorectal cancer varies globally: the incidence rate is 10 times higher and the mortality rate 5 times higher in countries with the highest rates than in countries with the lowest rates.
• Worldwide, colorectal cancer is the third most common cancer in men, the second most common cancer in women, and the fourth leading cause of cancer deaths.
• In the United States, colorectal cancer is the third most common cancer in both men and women (9% of the estimated incident cancer cases in both men and women in 2012) and the third leading cause of cancer deaths (9% of estimated cancer deaths in both men and women in 2012).
• There are geographic variations in incidence and mortality, with higher incidence but lower mortality rates in developed countries than in developing countries.
• Colorectal cancer incidence rates have been declining in the United States, and have been stable or declining in most developed countries but are rising in developing countries.
• The increasing risk of colorectal cancer in developing countries may be attributable to increased longevity, and adverse lifestyle changes including smoking, lack of physical activity, and adoption of a westernized diet.
• Colorectal cancer incidence and mortality rate vary by geographic location, age, sex, race/ethnicity, and over time.
• The prevalence of colorectal cancer is high because it has a relatively good prognosis. As a result, there are over 1 million colorectal cancer survivors in the United States.

Analytic epidemiology: assessment of determinants of colorectal cancer:

• Cross-sectional, case-control, and cohort study designs can be used to determine the association of suspected environmental, lifestyle, and other exposures with colorectal cancer risk. Randomized controlled trials are the gold standard for determining cause and effect.
• Factors that increase the risk of colorectal cancer include older age, African-American race/ethnicity, inherited predisposition syndromes, family history of colorectal cancer or colorectal polyps, inflammatory bowel disease, personal history of colorectal cancer or polyps, diabetes, obesity, physical inactivity, smoking, and alcohol.
• Many other probable risk factors are under investigation.

Introduction

In the last decade, cancer has become the leading cause of death in economically developed countries and the second leading cause of death in developing countries. Globally, colorectal cancer (CRC) is the third most common cancer in men, the second most common cancer in women, and the fourth leading cause of cancer deaths. In 2008, an estimated 665,000 men and 570,000 women were diagnosed with CRC, and 668,000 deaths were attributable to CRC, accounting for 8% of all cancer deaths [1].

Colorectal cancer incidence worldwide

There is almost a 10-fold variation in CRC incidence rates (proportion of newly diagnosed cases per year) worldwide for both sexes. CRC incidence rates are highest in Australia/New Zealand and Western Europe and lowest in Middle Africa and South-Central Asia [1] (Figure 1.1).

Figure 1.1 Estimated age-standardized incidence rate per 100,000 colorectum: both sexes, all ages [1].

Although developed countries account for almost two-thirds of CRC cases (with the exception of a few countries in Eastern Europe, Eastern Asia, and Spain), the rates in developed countries have mostly remained stable or declined over time, whereas rates in developing countries are rising [1;2]. These differences may be attributable to changes in lifestyle and environmental factors as well as underlying genetic susceptibility. The rapid increase in the cancer burden in developing countries is possibly due to population growth and aging, and adverse lifestyle changes such as increased smoking, physical inactivity, and westernized diets [3]. Worldwide, the age-standardized rate (ASR) for CRC incidence is 17.3 per 100,000 population and the cumulative risk for CRC from birth to age 74 years is 0.9% [1]. The incidence of CRC is higher in men than in women (overall male:female ratio of age-standardized rates is 1.4:1). Country-specific rates for CRC incidence and mortality are available from the GLOBCAN database from the World Health Organization's International Agency for Research on Cancer (http://globocan.iarc.fr/).

Colorectal cancer incidence, time trends, and lifetime risk in the United States (US)

It is estimated that 143,460 men and women (73,420 men and 70,040 women) will be diagnosed with CRC in the US in 2012 [4]. Of all CRCs diagnosed, about 72% affect the colon and the remaining 28% affect the rectum. Incidence rates for CRC in the US have declined roughly by 2–3% every year over the last 15–20 years [5], largely attributable to the advent of CRC screening, which allows for early detection and removal of precancerous polyps [6]. The lifetime incidence of CRC in the US is 5%, or 1 in 20 people are predicted to get CRC over their lifetime. The incidence of CRC is 25% higher in men than in women, and most (>90%) cases occur in men and women older than 50 years. Rates vary significantly by race/ethnicity; the incidence of CRC in African-American men is 20% higher than in white men [3].

Colorectal cancer mortality worldwide

CRC is the fourth most common cause of death from cancer, accounting for 8% of all cancer deaths worldwide. Globally, mortality rates continue to increase for deaths due to CRC (the ASR is 8.2/100,000). Cancer survival tends to be poorer in developing countries, possibly because cancer is diagnosed at later stages and patients have limited access to timely and standard care [3]. There is less variability in mortality rates worldwide (6 times higher in men and 5 times higher in women, in countries with the highest rates than in countries with the lowest rates), with the highest estimated mortality rates in both sexes in Central and Eastern Europe (20.1/100,000 for men and 12.2/100,000 for women), and the lowest in Middle Africa (3.5/100,000 for men and 2.7/100,000 for women) [1].

The mortality rate for CRC is roughly half the incidence rate, so its prognosis is relatively good. Thus, CRC has a high 5-year prevalence (number of cases in the population at a given time), with an estimated 3.26 million people alive with CRC diagnosed within the past 5 years [1;7]. The decrease in mortality may be due to changes in incidence, progress in therapy, improved early detection due to widespread screening, diagnosis at earlier stages (when the cancer is more amenable to treatment), and many other factors [8].

Colorectal cancer mortality in the US

An estimated 51,690 people will die of CRC in 2012 [4]. CRC-related deaths in the US have been declining steadily from 1975 to 2009, with an annual percentage change of 0.5–4% [4]. The US mortality rate for CRC from 2005 to 2009 was 16.7 per 100,000 patients per year. However, mortality rates varied significantly by both sex and race/ethnicity. Mortality rates are highest for African-American men (29.8/100,000) and lowest for Asian-Pacific Islander women (9.6/100,000). The largest proportion (29%) of CRC deaths occurred in patients aged 75–84 years, and the median age at death was 74 years [4]. The mortality rate for CRC is roughly one-third the incidence rate, resulting in a high prevalence of patients diagnosed with CRC. On January 1, 2009, over 1.14 million people with a history of CRC were alive in the US [4]. The 5-year survival rate for CRC is related to the stage at diagnosis; CRC diagnosed at the local stage has a 5-year survival rate of 90%, but the rate drops to only 12% if CRC is diagnosed after it has metastasized [9]. Overall, the US has one of the highest 5-year survival rates for CRC in the world: 61% for patients diagnosed at any stage.

Colorectal cancer risk factors

Epidemiologic studies have identified many factors that may increase or decrease risk of CRC. Some of these factors, such as a personal or family history of CRC or a history of inflammatory bowel disease, are non-modifiable, but many lifestyle risk factors, such as smoking, alcohol use, and lack of physical activity, are modifiable. It was recently reported that following a healthy lifestyle that includes being physically active for at least 30 minutes per day, following a healthy diet, controlling abdominal adiposity, not smoking, and not drinking alcohol in excess could have prevented 23% of the CRC cases in a cohort of more than 50,000 people aged 50–64 years, who were cancer-free at baseline and followed up for an average of 10 years [10]. Genetic susceptibility due to inherited germline mutations is the cause of CRC in about 5% of patients; however, most cases are sporadic, not familial.

Age

Age is a major risk factor influencing CRC incidence and death rate, because both rates increase with age. Over...

Produkt-Details

• Erscheint lt. Verlag: 12.2.2014
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie ► Allgemeines / Lexika
• Themenwelt: Medizinische Fachgebiete ► Innere Medizin ► Gastroenterologie
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
• Schlagworte: Aspects • authoritative • challenging • Chemotherapy • Colorectal Cancer • Diagnosis • forms • Gastroenterologie • gastroenterology • Gastrointestinal surgery • Guide • latest guidance • Magen-Darm-Chirurgie • managing colorectal cancer • Medical Science • Medizin • New • new strategies • Oncology & Radiotherapy • Onkologie u. Strahlentherapie • Practical • Practice • surgeons • Surgery • therapies • Treatment • various
• ISBN-10: 1-118-33789-1 / 1118337891
• ISBN-13: 978-1-118-33789-9 / 9781118337899